Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy
Clicks: 1
ID: 314099
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #73 of 98 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Rituximab (RTX) is effective first-line therapy for primary membranous nephropathy (PMN), but some patients respond poorly or develop anti-rituximab antibodies (ARA), leading to treatment failure. Obinutuzumab (OBZ), a humanized anti-CD20 monoclonal antibody, shows therapeutic potential in these patients. However, the emergence and clinical relevance of anti-obinutuzumab antibodies (AOA) remain unclear. We aimed to evaluate the role of AOA in PMN patients. METHOD: We retrospectively analyzed 23 PMN patients treated with OBZ, including 7 AOA-positive cases. Baseline characteristics, immunological and clinical remission outcomes were compared between AOA-positive and AOA-negative groups. Associations between AOA status, titer, cumulative exposure, and time to remission were assessed. RESULTS: AOA developed in 7 patients (30.4%), exclusively after ≥ 3 months of therapy (median seroconversion: 12.4 months [8.7-13.6]). AOA-positive patients were more frequently male (100% vs. 56.3%, P = 0.036), had higher baseline serum albumin (30.4 ± 6.2 vs. 24.4 ± 6.0 g/L, P = 0.04), and were more likely ARA-positive (85.7% vs. 18.8%, P = 0.005). No differences were observed in eGFR, UPCR, anti-PLA2R titers, or CD19⁺ B-cell counts at baseline. Immunological remission rates were comparable (100% vs. 92.3%, P = 0.452); clinical remission was achieved in 85.7% vs. 60.0% (P = 0.228). Kaplan-Meier analysis showed no significant difference in time to clinical (P = 0.48) or immunological remission (P = 0.21). Among AOA-positive patients, higher baseline AOA titer (Spearman r = 0.829, P = 0.042) and greater cumulative AOA exposure (AUC; r = 0.943, P = 0.017) strongly correlated with delayed clinical remission. CONCLUSION: 30.4% of PMN patients with OBZ therapy were tested positive for AOA. Although no statistically significant association was observed between AOA status and treatment outcomes, higher AOA titers and greater cumulative exposure were associated with slower clinical remission, suggesting a modulatory effect on OBZ efficacy in our PMN cohort.
| Reference Key |
openalex_W7161640695
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yang Liu, Yuan Cheng, Di Wu, Haofei Hu, Yuna Chen, Qijun Wan |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag104
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.